HKIB Advanced Therapy Products (ATP) Good Manufacturing Practice (GMP) Centre designed to comply with PIC/S GMP Standard will open in 2022. It will offer academic and non-academic collaborators flexible manufacturing solutions without the capital investment of building its own. It gives acceleration of clinical trials to commercial scale production and offers certainty of manufacturing future.
HKIB operates a state-of-the-art Current Good Manufacturing Practice (cGMP) production facility for advanced therapy products. As the leading manufacturer in Hong Kong, HKIB can translate your academic cell therapy protocols to GMP, process development and the associated documentation required for GMP manufacturing for the use in clinical trials.
創科發展日漸成熟，癌症治療亦邁向科技化。中文大學成立「先進治療產品良好生產規範中心」下月正式啟用，是本港首個製造細胞及基因治療產品的科研機構，以基因改造細胞技術治療癌症、骨骼衰弱等，以往依賴海外完成的基因改造程序，有望改為本地研發，節省時間及成本；中心將與本地兩所醫院合作臨牀治療及研究。校長段崇智指，中心將積極推動生物醫學科技的研究，並歡迎其他院校加入。
CUHK has entered into a new partnership with the Hong Kong Science and Technology Parks Corporation (HKSTP) to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine and related biomedical technologies.
The Chinese University of Hong Kong (CUHK) and Hong Kong Science and Technology Parks Corporation (HKSTP), announce their partnership to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine, and related biomedical technologies.
The Chinese University of Hong Kong (CUHK) will commence clinical trials of Chimeric antigen receptor-T cell (CAR-T cell) therapy, with the first phase targeting patients with haematological malignancy. The plan is to increase the survival rate and prolong overall survival for these patients.
